Skip to content

Released Nov 7, 2017, after the close

10-Q filed Nov 7, 2017, 38 days after period end · 0001232524-17-000179

Q3 2017 · 10-Q
Revenue$411.86M+10.1% vs Q3 2016+4.4% vs Q2 2017
Net Income$63.53M−29.3% vs Q3 2016−39.8% vs Q2 2017
EPS Diluted$1.03−29.0% vs Q3 2016−40.1% vs Q2 2017
Gross Profit$376,768,000+8.5%
Operating Income$86,454,000−36.5%
Operating Cash Flowderived$188,897,000+42.0%
Free Cash Flowderived$180,550,000+38.2%
Margins · derived
Gross margin91.5%−1.3 pt vs Q3 2016
Operating margin21.0%−15.4 pt vs Q3 2016
Net margin15.4%−8.6 pt vs Q3 2016

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ3 2017Q3 2016Q3 2015Q3 2014
Revenue$411.86M$374.18M$340.87M$306.58M
Net Income$63.53M$89.83M$87.96M$25.77M
EPS Diluted$1.03$1.45$1.39$0.41

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Jazz Pharmaceuticals plc · CIK 1232524 · Engraved from SEC EDGAR